Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYRUS study of surovatamig in relapsed or refractory B-cell acute lymphoblastic leukemia
jRCT2051240250Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, open-label trial of surovatamig in B cell acute lymphoblastic leukemia (B-ALL) (6 arms), sponsored by AstraZeneca. Primary endpoints: Frequency of dose-limiting toxicities, Safety evaluation of AZD0486 and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
surovatamig
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on jRCT2051240250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240250.